Email LinkedIn Twitter



Medical Affairs Consortium
Our Medical Affairs Consortium Members:

  • Amgen
  • Astrazeneca
  • Bayer
  • Biogen
  • EMDSerono
  • Eisai
  • Genentech
  • Genzyme
  • Incyte
  • KyowaKirin
  • Medivation
  • Pfizer
  • Roche
  • Sanofi
  • Santen
  • Sunovion
  • Theravance
  • UCB
  • ViiV

What is the Medical Affairs Consortium?

The Medical Affairs Consortium service is a unique opportunity for the industry leaders to discuss key challenges, develop action-oriented solutions and uncover recent and future trends in regards to the function and its interactions with other critical functions.

Service Model:

Our research team establishes Medical Affairs research information from around the healthcare sector. Armed with these critical insights, our client members then embark on a networking and performance improvement conversation utterly unique to the industry.

Medical Affairs Consortium members have the following benefits:

  • Receive three customized research deliverables that help them compare their organization to the benchmark class
  • Get the chance to participate in three roundtable session to discuss their issues, solutions and best practices with the leaders from peer companies
  • Receive three roundtable discussion summaries that combine the lessons learned from these roundtable sessions

Know how real world data is used in Medical Affairs:

Now accepting topics for the First RoundTable of the 2017-2018 Medical Affairs Consortium cycle





Download Medical Research Sample



Search Medical Affairs or
View Our Most Recent Research:

Enter the Medical Affairs topic you wish to probe. Examples: “Key Opinion Leader,” “MSL”, “launch”, “advisory board.”

Best Practices in Improving Medical Affairs Booth Impact at Critical Medical Congresses (ID POP-292)
Pharmaceutical companies spend a lot of money and resources on the medical booth exhibits that showcase their pipeline and products at key medical co...
Read More Arrow Bullet
Best Practices in Establishing Medical Affairs Capabilities in Emerging Countries: Using Structure, Staffing, and Responsibilities to Create an Effective Medical Affairs Group in TMEA (ID POP-289)
With pharmaceutical companies facing diverse markets around the world, it is challenging to create and maintain an effective Medical Affairs group in...
Read More Arrow Bullet
Investigator Initiated Trials Management (ID POP-282)
As pharmaceutical and medical device companies improve their investigator-initiated trial (IIT) programs, it is critical to properly vet each proposa...
Read More Arrow Bullet
Benchmarking Field Medical & Field Outcomes and Pricing KOL Engagement Strategies (ID POP-288)
The growing demand for scientific and medical data in the biopharmaceutical industry has pushed organizations to develop effective KOL engagement str...
Read More Arrow Bullet

ConsortiumCalenderKey Events
(July to June Fiscal Year)

Q1
  • Launch First Medical Affairs Consortium Survey
  • Medical Affairs Executives Participate in the Survey
  • Q2
  • First Roundtable Peer Panel & Knowledge Exchange
  • Delivery of First Customized Analysis & Key Roundtable Insights
  • Launch Second Medical Affairs Consortium Survey
  • Q3
  • Second Roundtable Peer Panel & Knowledge Exchange
  • Delivery of Second Customized Analysis & Key Roundtable Insights
  • Launch Third Medical Affairs Consortium Survey
  • Q4
  • Third Roundtable Peer Panel & Knowledge Exchange
  • Delivery of Third Customized Analysis & Key Roundtable Insights
  • Collect Member Insights for Next Round of Research Topics
  • Schedule a Meeting with Our Experts

    go to top


     
    ACCESS AND INTELLIGENCE FOR ACHIEVING WORLD-CLASS EXCELLENCE
    Quick Links  Product RSS Feed
    Payment gateway
    Secured by PayPal

    Follow Us: 

    linkedin twitter slideshare youtube google + pinterest

    All contents copyright 1998-2020 Best Practices, LLC (919) 403-0251
    Read our Terms and Conditions of Use, Privacy Policy and Copyright Information